» Articles » PMID: 11323343

Modulation of NMDA Receptor Function by Ketamine and Magnesium: Part I

Overview
Journal Anesth Analg
Specialty Anesthesiology
Date 2001 Apr 27
PMID 11323343
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: N-methyl-D-aspartate (NMDA) receptors are important components of pain processing. Ketamine and Mg2+ block NMDA receptors and might therefore be useful analgesics, and combinations of Mg2+ and ketamine provide more effective analgesia. We investigated their interactions at NMDA receptors. Xenopus oocytes, expressing NR1/NR2A or NR1/NR2B glutamate receptors, were studied. The effects of Mg2+, racemic ketamine and its isomers, and the combination of Mg2+ and S(+)-ketamine on NMDA signaling were determined. Mg2+ and ketamine alone inhibited NMDA receptors noncompetitively (half-maximal inhibitory effect concentration: Mg2+ 4.2 +/- 1.2 x 10(-)(4) M at NR1/NR2A and 6.3 +/- 2.4 x 10(-)(4) M at NR1/NR2B; racemic ketamine 13.6 +/- 8.5 x 10(-)(6) M at NR1/NR2A and 17.6 +/- 7.2 x 10(-)(6) M at NR1/NR2B; S(+)-ketamine 4.1 +/- 2.5 x 10(-)(6) at NR1/NR2A and 3.0 +/- 0.3 at NR1/NR2B; R(-)-ketamine 24.4 +/- 4.1 x 10(-)(6) M at NR1/NR2A and 26.0 +/- 2.4 x 10(-)(6) M at NR1/NR2B). The combined application of Mg2+ and ketamine decreased the half-maximal inhibitory effect concentration >90% at both receptors. Isobolographic analysis demonstrated super-additive interactions. Ketamine and Mg2+ inhibit responses of recombinantly expressed NR1/NR2A and NR1/NR2B glutamate receptors, and combinations of the compounds act in a super-additive manner. These findings may explain, in part, why combinations of ketamine and Mg2+ are more effective analgesics than either compound alone.

Implications: Ketamine and Mg2+ inhibit functioning of recombinantly expressed NR1/NR2A and NR1/NR2B glutamate receptors, and combinations of the compounds act in a super-additive manner. These findings may explain, in part, why combinations of ketamine and Mg2+ are more effective analgesics than either compound alone.

Citing Articles

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?.

Levinstein M, Budinich R, Bonaventura J, Schatzberg A, Zarate Jr C, Michaelides M Am J Psychiatry. 2025; 182(3):247-258.

PMID: 39810555 PMC: 11872000. DOI: 10.1176/appi.ajp.20240378.


Intravenous Magnesium for the Management of Chronic Pain:An Updated Review of the Literature.

Onyeaka H, Adeola J, Xu R, Pappy A, Smucker M, Ufondu W Psychopharmacol Bull. 2024; 54(4):81-105.

PMID: 39263198 PMC: 11385265.


Magnesium (Mg): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation.

Kumar A, Mehan S, Tiwari A, Khan Z, Gupta G, Narula A Curr Pharm Des. 2024; 30(39):3074-3107.

PMID: 39253923 DOI: 10.2174/0113816128321466240816075041.


Allosteric inhibition of NMDA receptors by low dose ketamine.

Abbott J, Wen H, Liu B, Gupta S, Iacobucci G, Zheng W Mol Psychiatry. 2024; 30(3):1009-1018.

PMID: 39237721 DOI: 10.1038/s41380-024-02729-9.


Narrative Review: Low-Dose Ketamine for Pain Management.

Riccardi A, Guarino M, Serra S, Spampinato M, Vanni S, Shiffer D J Clin Med. 2023; 12(9).

PMID: 37176696 PMC: 10179418. DOI: 10.3390/jcm12093256.